Quantification of antibody-drug conjugate PYX-201 in rat and monkey plasma via ELISA and its application in preclinical studies

Bioanalysis. 2023 Jan;15(1):43-52. doi: 10.4155/bio-2022-0233. Epub 2023 Mar 6.

Abstract

Aim: PYX-201 is a novel antibody-drug conjugate targeting the extra domain B splice variant of fibronectin in the tumor microenvironment. Accurate quantification of PYX-201 is critical for PYX-201 pharmacokinetics profiling in preclinical studies. Materials & methods: ELISA was performed using reference standard PYX-201, mouse monoclonal anti-monomethyl auristatin E antibody, mouse IgG1, mouse monoclonal anti-human IgG horseradish peroxidase and donkey anti-human IgG horseradish peroxidase. Results: This assay was validated at 50.0-10,000 ng/ml in rat dipotassium EDTA plasma and 250-10,000 ng/ml in monkey dipotassium EDTA plasma. Conclusion: This is the first time for a PYX-201 bioanalytical assay in any matrix to be reported.

Keywords: ADC; Aur0101; ELISA; PYX-201; extra domain B fibronectin; oncology; preclinical; toxicokinetic; validation; vc0101.

MeSH terms

  • Animals
  • Edetic Acid
  • Enzyme-Linked Immunosorbent Assay
  • Immunoconjugates*
  • Immunoglobulin G
  • Mice
  • Rats

Substances

  • Immunoconjugates
  • Edetic Acid
  • Immunoglobulin G